Team:Heidelberg/Project/Mouse Infection

From 2010.igem.org

(Difference between revisions)
(in vivo study)
Line 1: Line 1:
-
{{:Team:Heidelberg/Double}}
+
=<i>in vivo</i> study=
-
{{:Team:Heidelberg/Pagetop|pro_mouse}}
+
-
 
+
-
=in vivo study=
+
==Abstract==
==Abstract==
==Introduction==
==Introduction==
-
 
-
The importance of virus shuttles for human gene therapy canot be understated. The Adeno-associated virus (AAV) is a non-pathogenic virus that can infect human tissue but does not replicate without a helper virus (like Adenovirus or Herpex simplex virus). Therefore it is ideal for the delivery of transgenes in vivo. AAVs are small (4.8kb genome size), nonenveloped viruses that exist in various natural serotypes with different properties in tropism and transduction speed and efficiency. The most intensively studied AAV serotype is AAV2, which is used in several ongoing clinical trials aiming at muscle tissue or central nervous system diseases. <br>
 
-
AAV viruses are easily manipulated, as they do not require any viral genes in cis (that is, on the same construct) genes needed for packaging (cap) and other structures (rep) that usually make up the viral genome can be delivered in trans from a second vector that is co-transfected. The only requirement for a gene to be packaged into an AAV virus is that it has to be flanked by Inverted Terminal Repeats (ITR) that serve as a packaging signal.
 
-
 
-
For delivery of our transgenes into mice, we chose AAV serotype 8 as a carrier. This serotype, which has been isolated from rhesus monkey, has been shown to infect rapidly and especially target heart and liver. Since we are using the liver-specific miRNA 122 for On- and Off-targeting, this would be our ideal vector.
 
-
 
===gene therapy===
===gene therapy===
-
====Adeno-associated viruses====
+
====Adeno-associated viruses (AAV)====
====miRNAs====
====miRNAs====
====bioluminescence imaging====
====bioluminescence imaging====
Line 19: Line 10:
==Results==
==Results==
===constructs===
===constructs===
-
 
+
The <i>in vivo</i> analysis should enlighten our gene therapy approach using AAV tropism as well as miRNA binding sites as trigger for expression. The following constructs have been subcloned separately into the AAV context to accomplish those tasks: <br/>
-
In order to enable in vivo analysis of our gene therapy approach using AAV tropism as well as miRNA binding sites as trigger for expression the following constructs have been subcloned into the AAV context: (1) positive control, (2) off-targeting construct, (3) synthetic tuning construct and (4) on-targeting construct. All but of one virus were packaged in the adeno-associated virus (AAV) rep and cap gene with Adenovirus 5 (Ad5) as a helper plasmid. Accordingly, one virus construct was packaged into a shuffled cap gene from our [https://2010.igem.org/Team:Heidelberg/Project/Capsid_Shuffling/Homology_Based homology based capsid shuffling] attempt.  
+
# positive control,  
-
 
+
# off-targeting construct,  
-
(1) The positive control consisted of the SV40 promoter driving a firefly luciferase (luc2) gene, thereby leading to an unspecific expression of the luciferase protein in all mice tissues.  
+
# synthetic tuning construct and  
-
In addition to packaging this construct into a wild type AAV virus, the positive control was also packaged as a transgene into our [https://2010.igem.org/Team:Heidelberg/Project/Capsid_Shuffling/Homology_Based shuffled capsid] which after selection pressure was already able to positively transduce Huh7 and HepG2 cells in cell culture.  
+
# on-targeting construct.  
-
 
+
<br/>
-
(2) The off-targeting construct was composed of an SV40 promoter driving a firefly luciferase (luc2) gene with binding sites against miR-122 behind it. In order to achieve the highest expression in all mice cells but the liver cells, a perfect binding site of miR-122 was used for in vivo study.  
+
All but one virus were packaged by the AAV rep and cap gene with Adenovirus 5 (Ad5) as a helper plasmid. Accordingly, one virus construct was packaged into a shuffled cap gene from our [https://2010.igem.org/Team:Heidelberg/Project/Capsid_Shuffling/Homology_Based homology based capsid shuffling] attempt.  
-
 
+
<br/>
-
(3) The synthetic tuning construct consisted of two viruses injected at the same time in the mice. The one virus packaged the expression construct of shRNA haat driven by the H1 promoter. The second virus packaged the following transgene: SV40 promoter driving luc2 with binding sites for shRNA haat behind it. In order to ensure a synthetic tuning effect a perfect binding site and one with a bulge that was introduced at position 9-12 were used for in vivo experiments, respectively. Those two binding sites should lead to a knockdown in the first case and a repression of luciferase expression in the latter in comparison to the positive control.
+
# The positive control (see sidebar, fig. 1) consisted of the SV40 promoter driving a firefly luciferase (luc2) gene, thereby leading to an unspecific expression of the luciferase protein in all mice tissues.  
-
 
+
In addition to packaging this construct into a wild type AAV virus, the positive control was also packaged as a transgene into our [https://2010.igem.org/Team:Heidelberg/Project/Capsid_Shuffling/Homology_Based shuffled capsid] which after random selection <!--selection pressure--> was already able to [https://2010.igem.org/Team:Heidelberg/Notebook/Homology_Based/October#16/10/2010 positively transduce Huh7 and HepG2 cells] <i>in vitro</i>.  
-
(4) The on-targeting construct consisted of two independent viruses which were co-infected into mice, as well. One of these viruses packaged the Tet Repressor (TetR) driven by an SV40 promoter. The expression of TetR is under the control of miR-122 as four binding sites of this miRNA were cloned into the 3’UTR of the gene. The second virus was composed of an sv40 promoter driving the Tet operator (TetO2) which monitors the expression of luc2. With this setup, luc2 expression should be inhibited by the TetR in all mice tissues except for liver cells, where TetR is downregulated by miRNA 122.
+
# The off-targeting construct (see sidebar, fig. 2) was composed of an SV40 promoter driving a firefly luciferase (luc2) gene with binding sites against miR-122 behind it. In order to achieve the highest expression in all mice cells but the liver cells - a single perfect binding site of miR-122 was used for <i>in vivo</i> study.  
 +
# The synthetic tuning construct (see sidebar, fig. 3) consisted of two viruses injected at the same time in the mice. The one virus packaged the expression construct of shRNA haat driven by the H1 promoter ("tuning" construct, see sidebar, fig.3). The second virus packaged the following transgene: SV40 promoter driving luc2 with shRNA haat binding site behind it ("tuned" construct, see sidebar, fig. 4). In order to ensure a synthetic tuning effect, a perfect binding site and one with a bulge that was introduced at position 9-12 were used for <i>in vivo</i> experiments, respectively. Those two binding sites should lead to a significant knockdown in the first case and a slight repression of luciferase expression in the latter as compared to the positive control.
 +
# The on-targeting construct consisted of two independent viruses which were co-infected into mice, as well. One of these viruses packaged the Tet Repressor (TetR) driven by an SV40 promoter ("repressor" construct, see sidebar, fig. 5). The expression of TetR is under the control of miR-122 as four binding sites of this miRNA were cloned into the 3’UTR of the gene. The second virus was composed of an SV40 promoter driving the Tet operator (TetO<sub>2</sub>) which monitors the expression of luc2 ("operator" construct, see sidebar, fig. 6). With this setup, luc2 expression should be inhibited by the TetR in all mice tissues except for liver cells, where TetR is down-regulated by miRNA 122.
===mice injection===
===mice injection===
Line 43: Line 36:
===contructs===
===contructs===
===production of recombinant virus===
===production of recombinant virus===
-
The viruses were produced on HEK 293-T cells and purified on an iodixanol gradient according to [https://2010.igem.org/Team:Heidelberg/Notebook/Methods#Virus_Production protocol].  
+
The viruses were produced in HEK 293-T cells and purified on an iodixanol gradient according to [https://2010.igem.org/Team:Heidelberg/Notebook/Methods#Virus_Production the virus production protocol].  
Before infection, the titer of the viruses was quantified using [https://2010.igem.org/Team:Heidelberg/Notebook/Methods#Quantitative_Realtime_PCR quantitative realtime PCR].
Before infection, the titer of the viruses was quantified using [https://2010.igem.org/Team:Heidelberg/Notebook/Methods#Quantitative_Realtime_PCR quantitative realtime PCR].
===procedure involving animals===
===procedure involving animals===
-
The mouse experiments were conducted in accordance with the animal facility of the german cancer research institute of Heidelberg. Female NMRI mice were purchased from....??. At 8-10 weeks of age the animals were injected in the tail vein (TV), with ~1x10^11 particles of AAV-SV40-luciferase in 200µl of 1x phosphate-buffered saline. The mice are transferred to a holding device which restrains the mouse while allowing access to the tail vein. The tails were warmed before the injections and injections were carried out usind 27 gauge needles. All the mice recoverd from the injection quickly without loss of mobility or interruption of grooming activity.
+
The mouse experiments were conducted in accordance with the animal facility of the [https://2010.igem.org/Team:Heidelberg/Team/Institutes german cancer research institute of Heidelberg]. Female NMRI mice were purchased from....??. At 8-10 weeks of age, the animals were injected in the tail vein (TV), with <nowiki>~</nowiki> 1x10<sup>11</sup> particles of AAV-SV40-luciferase in 200µl of 1x phosphate-buffered saline. The mice are transferred to a holding device which restrains the mouse while allowing access to the tail vein. The tails were warmed before the injections and injections were carried out using 27 gauge needles. All the mice recoverd from the injection quickly without loss of mobility or interruption of grooming activity {{HDref|Zincarelli et al., 2008}}.
===in vivo animal imaging===
===in vivo animal imaging===
Line 56: Line 49:
{{:Team:Heidelberg/Pagemiddle}}
{{:Team:Heidelberg/Pagemiddle}}
-
 
__TOC__
__TOC__
 +
<br/>
 +
==== construct schemes ====
 +
[Image:PBS SV40 luc2.png|thumb|center|300px|'''Figure 1: Positive control construct.''']
 +
<br/>
 +
[Image:PBS SV40 luc2 miR122.png|thumb|center|300px|'''Figure 2: Off-targeting construct.''']
 +
<br/>
 +
[Image:PBS_H1_shR_hAAT.png|thumb|center|300px|'''Figure 3: Tuning construct.''']
 +
<br/>
 +
[Image:PBS SV40 luc2 hAAT.png|thumb|center|300px|'''Figure 4: Tuned construct.''']
 +
<br/>
 +
[Image:Image:PBS TetR miR122 4x.png|thumb|center|300px|'''Figure 5: Repressor construct.''']
 +
<br/>
 +
[Image:Image:PBS SV40 TetO2 luc2.png|thumb|center|300px|'''Figure 6: Operator construct.''']
{{:Team:Heidelberg/Bottom}}
{{:Team:Heidelberg/Bottom}}

Revision as of 13:22, 27 October 2010

in vivo study

Abstract

Introduction

gene therapy

Adeno-associated viruses (AAV)

miRNAs

bioluminescence imaging

Results

constructs

The in vivo analysis should enlighten our gene therapy approach using AAV tropism as well as miRNA binding sites as trigger for expression. The following constructs have been subcloned separately into the AAV context to accomplish those tasks:

  1. positive control,
  2. off-targeting construct,
  3. synthetic tuning construct and
  4. on-targeting construct.


All but one virus were packaged by the AAV rep and cap gene with Adenovirus 5 (Ad5) as a helper plasmid. Accordingly, one virus construct was packaged into a shuffled cap gene from our homology based capsid shuffling attempt.

  1. The positive control (see sidebar, fig. 1) consisted of the SV40 promoter driving a firefly luciferase (luc2) gene, thereby leading to an unspecific expression of the luciferase protein in all mice tissues.

In addition to packaging this construct into a wild type AAV virus, the positive control was also packaged as a transgene into our shuffled capsid which after random selection was already able to positively transduce Huh7 and HepG2 cells in vitro.

  1. The off-targeting construct (see sidebar, fig. 2) was composed of an SV40 promoter driving a firefly luciferase (luc2) gene with binding sites against miR-122 behind it. In order to achieve the highest expression in all mice cells but the liver cells - a single perfect binding site of miR-122 was used for in vivo study.
  2. The synthetic tuning construct (see sidebar, fig. 3) consisted of two viruses injected at the same time in the mice. The one virus packaged the expression construct of shRNA haat driven by the H1 promoter ("tuning" construct, see sidebar, fig.3). The second virus packaged the following transgene: SV40 promoter driving luc2 with shRNA haat binding site behind it ("tuned" construct, see sidebar, fig. 4). In order to ensure a synthetic tuning effect, a perfect binding site and one with a bulge that was introduced at position 9-12 were used for in vivo experiments, respectively. Those two binding sites should lead to a significant knockdown in the first case and a slight repression of luciferase expression in the latter as compared to the positive control.
  3. The on-targeting construct consisted of two independent viruses which were co-infected into mice, as well. One of these viruses packaged the Tet Repressor (TetR) driven by an SV40 promoter ("repressor" construct, see sidebar, fig. 5). The expression of TetR is under the control of miR-122 as four binding sites of this miRNA were cloned into the 3’UTR of the gene. The second virus was composed of an SV40 promoter driving the Tet operator (TetO2) which monitors the expression of luc2 ("operator" construct, see sidebar, fig. 6). With this setup, luc2 expression should be inhibited by the TetR in all mice tissues except for liver cells, where TetR is down-regulated by miRNA 122.

mice injection

In order to assess tissue tropism of the The TVroute was chosen so as to assess AAV serotype tissue tropism; the luciferase transgene was used for visualizing the relative vector distribution in all the animals in a real-time manner

bioluminescence imaging

Discussion

Methods

contructs

production of recombinant virus

The viruses were produced in HEK 293-T cells and purified on an iodixanol gradient according to the virus production protocol.

Before infection, the titer of the viruses was quantified using quantitative realtime PCR.

procedure involving animals

The mouse experiments were conducted in accordance with the animal facility of the german cancer research institute of Heidelberg. Female NMRI mice were purchased from....??. At 8-10 weeks of age, the animals were injected in the tail vein (TV), with ~ 1x1011 particles of AAV-SV40-luciferase in 200µl of 1x phosphate-buffered saline. The mice are transferred to a holding device which restrains the mouse while allowing access to the tail vein. The tails were warmed before the injections and injections were carried out using 27 gauge needles. All the mice recoverd from the injection quickly without loss of mobility or interruption of grooming activity (Zincarelli et al., 2008).

in vivo animal imaging

References

This page is still under construction.

Contents


construct schemes

[Image:PBS SV40 luc2.png|thumb|center|300px|Figure 1: Positive control construct.]
[Image:PBS SV40 luc2 miR122.png|thumb|center|300px|Figure 2: Off-targeting construct.]
[Image:PBS_H1_shR_hAAT.png|thumb|center|300px|Figure 3: Tuning construct.]
[Image:PBS SV40 luc2 hAAT.png|thumb|center|300px|Figure 4: Tuned construct.]
[Image:Image:PBS TetR miR122 4x.png|thumb|center|300px|Figure 5: Repressor construct.]
[Image:Image:PBS SV40 TetO2 luc2.png|thumb|center|300px|Figure 6: Operator construct.]